HDM-SPIRE

Drug Profile

HDM-SPIRE

Alternative Names: Antiallergy vaccine house dust mite - Circassia; House dust mite allergy immunotherapy - Circassia; House dust mite allergy vaccine - Circassia; House dust mite SPIRE; ToleroMune HDM; ToleroMune house dust mite

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Circassia
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 13 Apr 2017 Circassia completes a phase II trial in Allergic rhinoconjunctivitis in USA, Canada, France, Germany, Italy, Latvia, Lithuania, Netherlands, South Africa, Spain (NCT02150343)
  • 28 Jul 2015 Phase-II development is ongoing in Canada, France, Germany, Italy, Netherlands, South Africa, Spain and USA
  • 01 Sep 2014 Phase-II clinical trials in Allergic rhinoconjunctivitis in USA, Germany, Italy and the Netherlands (Intradermal) (NCT02150343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top